Expert Review on Biosimilars in Oncology and Hematology |
Expert review with Matti Aapro, MD, Håkan Mellstedt, MD, PhD, Jos Kosterink, PharmD, PhD, and Luciano Wannesson, MD, focusing on biosimilars in oncology and hematology. |
| Moderator |
|
 |
Matti Aapro, MD
Clinique de Genolier
Genolier, Switzerland |
| Discussants |
|
 |
Jos Kosterink, PharmD, PhD
University Medical Center Groningen
Groningen, the Netherlands |
 |
Håkan Mellstedt, MD, PhD
Karolinska Institute
Stockholm, Sweden |
 |
Luciano Wannesson, MD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland |
|
Discussion Topics |
- Introduction to biosimilars
- The biosimilars regulatory approval process
- Biosimilar monoclonal antibodies
- Major concerns regarding biosimilar use, including extrapolation, immunogenicity, and traceability
- Economics of biosimilars
|
Learning Objectives |
- Compare the safety and efficacy of biosimilar drugs to their originator
- Analyze major issues of contention regarding biosimilar use, including extrapolation, traceability, and automatic substitution, and propose solutions to address these issues
- Discuss the positive and negative aspects of biosimilar monoclonal antibody development and use
- Explain the regulatory approval process for biosimilars with a focus on how this differs from the process for other biologic products
|
|
|
|
Activity Date | This interview is available from 9 May 2011 to 9 May 2012.
|
Audience | This educational activity is specifically designed for physicians and other healthcare professionals involved and/or interested in the use of biologic and biosimilar medicines. |
Support | This educational activity is supported by Amgen Europe, GmbH and F. Hoffmann-La Roche Ltd.
|
|
